Sudarshan Pharma Industries Limited has informed the Exchange about issue of Securities - In continuation of the Company''s letter dated 30/Oct/2026 (ref. no. SPIL/CS/2026-2027/72), the Board of Directors at its Meeting held on 29/Oct/2026 have approved the proposal to raising of funds through issue and allotment of Convertible Warrants upto an amount not exceeding Rs.72 Crores, each warrant convertible into 1 equity share of Re1/- each, on a preferential basis to Mr. Hemal Mehta and Mr. Sachin Mehta, Promoters of the Company. The Warrants shall be issued at a price to be determined as per Regulation 164 of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.
According to primary filings and dispatches highlighted by NSE India, the latest move impacts key counters including relevant market segments. Market analysts note that volume activity and corporate disclosures indicate significant retail and domestic institutional engagement with the development.
Terminal indicators suggest a balanced risk-reward profile, with institutional participants waiting for confirmation from subsequent quarterly prints or macro cues. Range-bound consolidation is expected in the near term as market participants digest the broader ramifications of the announcement.
Investors and intraday participants are advised to monitor official exchange disclosures on BSE and NSE, alongside subsequent management commentary. ZeroLive will continue monitoring real-time order book developments, price action triggers, and regulatory updates as they unfold.